Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis.

What It Covers

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a meta-analysis.

Vitamin D is widely used to manage chronic kidney disease-mineral and bone disorder (CKD-MBD).

The researchers evaluated the effects of vitamin D therapy on mortality, cardiovascular, bone, and kidney outcomes in adults with CKD.

Why It Was Studied

RCTs with≥3 months of follow-up evaluating a vitamin D compound.

Data were extracted independently by three investigators.

Who the Included Studies Covered

The age groups tagged for this paper are adults.

Adults with stage 3, 4, or 5 CKD, including kidney failure treated with dialysis.

How the Review Was Done

Systematic review of randomized controlled trials (RCT) with highly sensitive searching of MEDLINE, Embase, and CENTRAL, through February 25, 2023.

Recipients of a kidney transplant were excluded.

Risk of bias was assessed using the Cochrane Risk of Bias (RoB) 2 tool.

What Was Measured

RCTs with≥3 months of follow-up evaluating a vitamin D compound.

Secondary outcomes were major adverse cardiovascular events, hospitalization, bone mineral density, parathyroidectomy, progression to kidney failure, proteinuria, estimated glomerular filtration rate, hypercalcemia, hyperphosphatemia, biochemical markers of CKD-MBD, and various intermediate outcome measures of cardiovascular disease.

PubMed files the paper under topics including Vitamin D, Renal Insufficiency, Chronic, Randomized Controlled Trials as Topic, Chronic Kidney Disease-Mineral and Bone Disorder, Vitamins, Cardiovascular Diseases and Bone Density.

Author keywords: Bone mineral density, chronic kidney disease–mineral and bone disorder, kidney failure, meta-analysis and secondary hyperparathyroidism.

What This Means in Plain Language

This is a meta-analysis of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.